, Volume 178, Issue 2–3, pp 167–173

Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients

  • Roel Verheul
  • Philippe Lehert
  • Peter J. Geerlings
  • Maarten W. J. Koeter
  • Wim van den Brink
Original Investigation



Acamprosate is a proven effective intervention in the treatment of alcohol dependence. However, acamprosate prevents lapses or relapses only in a minority of patients. An important question, therefore, is whether there is a specific subgroup of patients who respond particularly well to acamprosate.


To identify predictors of acamprosate efficacy. Based upon the available evidence and hypotheses about the mechanisms underlying acamprosate’s effects on drinking behavior, the following variables were considered to be potential positive predictors: high physiological dependence at baseline, negative family history of alcoholism, late age-of-onset, serious anxiety symptomatology at baseline, severe craving at baseline, and female gender.


Potential predictors of acamprosate’s efficacy were analyzed in a pooled analysis of data from seven randomized placebo-controlled trials involving a total of 1485 patients with alcohol dependence. Outcome is measured in terms of cumulative abstinence duration (CAD), continuous abstinence (ABST), and time to first relapse (TFR).


CAD and ABST were predicted by baseline measures of craving and anxiety, as well as by study and treatment condition. Acamprosate efficacy was not differentially associated with any of the predictor variables. Importantly, the hypotheses were rejected despite the large sample size and sufficient statistical power.


The most straight-forward clinical implication of this study is that acamprosate can be considered as a potentially effective pharmacotherapy for all patients with alcohol dependence. The effect size of acamprosate alone is, however, moderate. Some evidence indicates that the combination of acamprosate with naltrexone or disulfiram leads to substantially better outcomes.


Campral Acamprosate Efficacy Effectiveness Predictors Patient-treatment matching 


  1. Ait-Daoud N, Johnson BA, Prihoda TJ et al. (2001) Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 154:23–27Google Scholar
  2. Anderson TW (1957) Maximum likelihood estimates for a multivariate normal distribution when some observations are missing. J Am Statist Assoc 52:200–203Google Scholar
  3. Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573–579Google Scholar
  4. Chick J, Howlett H, Morgan MY et al. (2000) United Kingdom Multicenter Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35:176–188Google Scholar
  5. Choi CC (1998) Sample size in clinical trials with dichotomous endpoints, use of covariables. J Biopharm Stat 8:367–375Google Scholar
  6. Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236:410–416Google Scholar
  7. Fleiss J (1985) Design and analysis of clinical experiments. Wiley, New York, pp 100–101Google Scholar
  8. Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 3:129–137Google Scholar
  9. Gerra G, Caccavari R, Delsignore R et al. (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res 52:291–295Google Scholar
  10. Gerra G, Ferri M, Zaimovic A et al. (1998) GABAergic function in detoxified heroin addicts: relationship to anxiety disorders. Psychiatry Res 77:89–96Google Scholar
  11. Gual A, Lehert Ph (2001) Acamprosate during and after acute alcohol withdrawal: a double blind placebo controlled study in Spain. Alcohol Alcohol 36:413–418Google Scholar
  12. Johnson BA, Roache JD, Javors MA et al. (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284:963–971Google Scholar
  13. Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92–99Google Scholar
  14. Koele P (1982) Calculating power in analysis of variance. Psychol Bull 92:513–516Google Scholar
  15. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335–1341Google Scholar
  16. Ladewig D, Knecht T, Lehert P et al. (1993) Acamprosate: a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50:182–188Google Scholar
  17. Lehert Ph (1994) Guidelines on evaluation of treatment of alcohol dependence. Alcoholism 59:67Google Scholar
  18. Lesch OM, Walter H (1996) Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 31(Suppl):63–67Google Scholar
  19. Little RJA, Rubin DB (1987) Statistical analysis with missing data. Wiley, New YorkGoogle Scholar
  20. Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90:1179–1188Google Scholar
  21. Littleton J, al Qatari M, Little H (1996) The neurobiology of craving: potential mechanisms for acamprosate. In: Soyka M (ed) Acamprosate in relapse prevention of alcoholism. Springer, Berlin Heidelberg New York, pp 27–46Google Scholar
  22. Mason BJ (2001) Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 62(Suppl 20):42–48Google Scholar
  23. Monterosso JR, Flannery BA, Pettinati H et al. (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258–268Google Scholar
  24. Oslin DW, Berrettini W, Kranzler HR et al. (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546–1552Google Scholar
  25. Pelc I, Verbanck P, Le Bon O et al. (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171:73–77Google Scholar
  26. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537–1546Google Scholar
  27. Samson HH, Harris RA (1992) The neurobiology of alcohol abuse. Trends Pharmacol Sci 13:206–211Google Scholar
  28. Sass H (1995) Results from a pooled analysis of 11 European trials comparing acamprosate and placebo in the treatment of alcohol dependence [abstract]. Alcohol Alcohol 30:551Google Scholar
  29. Sass H, Soyka M, Mann K et al. (1996) Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673–680Google Scholar
  30. Schuckit MA (1996) Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64:669–676Google Scholar
  31. Spanagel R, Zieglgänsberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18:54–59Google Scholar
  32. Tempesta E, Janiri L, Bignamini A et al. (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence. A placebo-controlled study. Alcohol Alcohol 35:202–209Google Scholar
  33. Tsai GE, Ragan P, Chang R et al. (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 155:726–732Google Scholar
  34. Van den Brink W (2003) The role of psychosocial interventions in the pharmacological treatment of alcohol dependence. Drugs Ther Perspect 2:16–21Google Scholar
  35. Verheul R, van den Brink W, Geerlings PJ (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34:197–222Google Scholar
  36. Whitworth AB, Fischer F, Lesch OM et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438–1442Google Scholar
  37. Wilde MI, Wagstaff AJ (1997) Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53:1038–1053Google Scholar
  38. Winer BJ (1989) Statistical principles in experimental design, 3rd edn. McGraw Hill, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Roel Verheul
    • 1
    • 2
  • Philippe Lehert
    • 3
    • 4
  • Peter J. Geerlings
    • 5
    • 6
  • Maarten W. J. Koeter
    • 6
    • 7
  • Wim van den Brink
    • 6
    • 7
  1. 1.Department of Clinical PsychologyUniversity of Amsterdam AmsterdamThe Netherlands
  2. 2. Viersprong Institute for Studies on Personality Disorder (VISPD) Center of Psychotherapy “De Viersprong”HalsterenThe Netherlands
  3. 3.Faculty of MedicineMelbourneAustralia
  4. 4.Faculty of EconomicsMonsBelgium
  5. 5.The Jellinek ClinicAmsterdamThe Netherlands
  6. 6.Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  7. 7.Amsterdam Institute of Addiction ResearchAmsterdamThe Netherlands

Personalised recommendations